BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 23028699)

  • 1. Cysteine dioxygenase 1 is a tumor suppressor gene silenced by promoter methylation in multiple human cancers.
    Brait M; Ling S; Nagpal JK; Chang X; Park HL; Lee J; Okamura J; Yamashita K; Sidransky D; Kim MS
    PLoS One; 2012; 7(9):e44951. PubMed ID: 23028699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic regulation of the novel tumor suppressor cysteine dioxygenase 1 in esophageal squamous cell carcinoma.
    Kwon J; Park M; Kim JH; Lee HW; Kang MC; Park JH
    Tumour Biol; 2015 Sep; 36(10):7449-56. PubMed ID: 25903467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Significance of Promoter DNA Hypermethylation of cysteine dioxygenase 1 (CDO1) Gene in Primary Breast Cancer.
    Minatani N; Waraya M; Yamashita K; Kikuchi M; Ushiku H; Kojo K; Ema A; Nishimiya H; Kosaka Y; Katoh H; Sengoku N; Tanino H; Sidransky D; Watanabe M
    PLoS One; 2016; 11(1):e0144862. PubMed ID: 26785325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylated cysteine dioxygenase-1 gene promoter in the serum is a potential biomarker for hepatitis B virus-related hepatocellular carcinoma.
    Yang Y; Fan YC; Gao S; Dou CY; Zhang JJ; Sun FK; Wang K
    Tohoku J Exp Med; 2014 Mar; 232(3):187-94. PubMed ID: 24646840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of methylated CDO1 in plasma of colorectal cancer; a PCR study.
    Yamashita K; Waraya M; Kim MS; Sidransky D; Katada N; Sato T; Nakamura T; Watanabe M
    PLoS One; 2014; 9(12):e113546. PubMed ID: 25469504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Efficacy of Postoperative Chemotherapy by DNA Methylation of CDO1 in Gastric Cancer.
    Harada H; Soeno T; Yokoi K; Nishizawa N; Ushiku H; Hosoda K; Hiki N; Yamashita K
    J Surg Res; 2020 Dec; 256():404-412. PubMed ID: 32777557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.
    Meller S; Zipfel L; Gevensleben H; Dietrich J; Ellinger J; Majores M; Stein J; Sailer V; Jung M; Kristiansen G; Dietrich D
    Epigenetics; 2016 Dec; 11(12):871-880. PubMed ID: 27689475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent inactivation of cysteine dioxygenase type 1 contributes to survival of breast cancer cells and resistance to anthracyclines.
    Jeschke J; O'Hagan HM; Zhang W; Vatapalli R; Calmon MF; Danilova L; Nelkenbrecher C; Van Neste L; Bijsmans IT; Van Engeland M; Gabrielson E; Schuebel KE; Winterpacht A; Baylin SB; Herman JG; Ahuja N
    Clin Cancer Res; 2013 Jun; 19(12):3201-11. PubMed ID: 23630167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-specific promoter DNA methylation of Cysteine dioxygenase type 1 (CDO1) gene as an important prognostic biomarker of gastric cancer.
    Harada H; Hosoda K; Moriya H; Mieno H; Ema A; Ushiku H; Washio M; Nishizawa N; Ishii S; Yokota K; Tanaka Y; Kaida T; Soeno T; Kosaka Y; Watanabe M; Yamashita K
    PLoS One; 2019; 14(4):e0214872. PubMed ID: 30934021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential Prognostic Relevance of Promoter DNA Methylation of
    Tanaka Y; Kosaka Y; Waraya M; Yokota K; Harada H; Kaida T; Kikuchi M; Minatani N; Nishimiya H; Katoh H; Sengoku N; Watanabe M; Yamashita K
    Anticancer Res; 2019 May; 39(5):2289-2298. PubMed ID: 31092420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic Status of CDO1 Gene May Reflect Chemosensitivity in Colon Cancer with Postoperative Adjuvant Chemotherapy.
    Yokoi K; Harada H; Yokota K; Ishii S; Tanaka T; Nishizawa N; Shimazu M; Kojo K; Miura H; Yamanashi T; Sato T; Nakamura T; Watanabe M; Yamashita K
    Ann Surg Oncol; 2019 Feb; 26(2):406-414. PubMed ID: 30311169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cysteine dioxygenase type 1 (CDO1) gene promoter methylation during the adenoma-carcinoma sequence in colorectal cancer.
    Kojima K; Nakamura T; Ohbu M; Katoh H; Ooizumi Y; Igarashi K; Ishii S; Tanaka T; Yokoi K; Nishizawa N; Yokota K; Kosaka Y; Sato T; Watanabe M; Yamashita K
    PLoS One; 2018; 13(5):e0194785. PubMed ID: 29746493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant promoter methylation and tumor suppressive activity of the DFNA5 gene in colorectal carcinoma.
    Kim MS; Chang X; Yamashita K; Nagpal JK; Baek JH; Wu G; Trink B; Ratovitski EA; Mori M; Sidransky D
    Oncogene; 2008 Jun; 27(25):3624-34. PubMed ID: 18223688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel colorectal cancer biomarkers CDO1, ZSCAN18 and ZNF331 are frequently methylated across gastrointestinal cancers.
    Vedeld HM; Andresen K; Eilertsen IA; Nesbakken A; Seruca R; Gladhaug IP; Thiis-Evensen E; Rognum TO; Boberg KM; Lind GE
    Int J Cancer; 2015 Feb; 136(4):844-53. PubMed ID: 24948044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (CDO1) promoter DNA in pancreatic cancer.
    Nishizawa N; Harada H; Kumamoto Y; Kaizu T; Katoh H; Tajima H; Ushiku H; Yokoi K; Igarashi K; Fujiyama Y; Okuwaki K; Iwai T; Watanabe M; Yamashita K
    Cancer Sci; 2019 Sep; 110(9):2846-2855. PubMed ID: 31325200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylated promoter DNA of CDO1 gene and preoperative serum CA19-9 are prognostic biomarkers in primary extrahepatic cholangiocarcinoma.
    Nakamoto S; Kumamoto Y; Igarashi K; Fujiyama Y; Nishizawa N; Ei S; Tajima H; Kaizu T; Watanabe M; Yamashita K
    PLoS One; 2018; 13(10):e0205864. PubMed ID: 30325974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of promoter DNA hypermethylation of the cysteine dioxygenase 1 (CDO1) gene in primary gallbladder cancer and gallbladder disease.
    Igarashi K; Yamashita K; Katoh H; Kojima K; Ooizumi Y; Nishizawa N; Nishiyama R; Kawamata H; Tajima H; Kaizu T; Kumamoto Y; Watanabe M
    PLoS One; 2017; 12(11):e0188178. PubMed ID: 29161283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoter DNA methylation of CDO1 gene and its clinical significance in esophageal squamous cell carcinoma.
    Ushiku H; Yamashita K; Katoh H; Ema A; Minatani N; Kikuchi M; Kojo K; Yokoi K; Tanaka T; Nishizawa N; Ishii S; Hosoda K; Moriya H; Mieno H; Katada N; Kikuchi S; Watanabe M
    Dis Esophagus; 2017 Feb; 30(2):1-9. PubMed ID: 27629777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted demethylation of the CDO1 promoter based on CRISPR system inhibits the malignant potential of breast cancer cells.
    Yang J; Sun L; Liu XY; Huang C; Peng J; Zeng X; Zheng H; Cen W; Xu YX; Zhu W; Wu XY; Ling D; Zhang LL; Wei M; Liu Y; Wang D; Wang FH; Li YH; Li Q; Du Z
    Clin Transl Med; 2023 Sep; 13(9):e1423. PubMed ID: 37740473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome.
    Deckers IA; Schouten LJ; Van Neste L; van Vlodrop IJ; Soetekouw PM; Baldewijns MM; Jeschke J; Ahuja N; Herman JG; van den Brandt PA; van Engeland M
    Clin Cancer Res; 2015 Aug; 21(15):3492-500. PubMed ID: 25904753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.